Literature DB >> 25178362

Seroprevalence of aquaporin-4-IgG in a northern California population representative cohort of multiple sclerosis.

Sean J Pittock1, Vanda A Lennon2, Nandini Bakshi3, Ling Shen4, Andrew McKeon1, Hong Quach5, Farren B S Briggs5, Allan L Bernstein6, Catherine A Schaefer4, Lisa F Barcellos7.   

Abstract

IMPORTANCE: Using an aquaporin-4 (AQP4) M1-isoform-specific enzyme-linked immunosorbent assay (ELISA) and a fixed transfected cell-based assay (CBA), we tested AQP4-IgG in a northern California population representative cohort of 3293 potential cases with multiple sclerosis (MS). Seropositive cases were tested additionally by fluorescence-activated cell sorting, a live transfected cell-based assay. OBSERVATIONS: Sera samples were available in 1040 cases; 7 yielded positive results, 4 by ELISA alone and 3 by both ELISA and CBA. Clinical data (episodes of optic neuritis and longitudinally extensive transverse myelitis [reported on at least 1 magnetic resonance imaging spine]) supported the alternative diagnosis of neuromyelitis optica for 2 patients as seropositive by both ELISA and CBA. These 2 patients alone tested positive by a fluorescence-activated cell-sorting assay. The diagnosis of MS was considered correct in the other 5 patients. Thus, 5 ELISA results and 1 fixed CBA result were false positive. CONCLUSIONS AND RELEVANCE: Sensitive serological evaluation for AQP4-IgG in this large population-representative cohort of predominantly white non-Hispanic patients with MS reveals that neuromyelitis optica spectrum disorder is rarely misdiagnosed as MS in contemporary US neurological practice (0.2%). The frequency of a false-positive result for ELISA and CBA in this MS cohort were 0.5% and 0.1%, respectively. This finding reflects the superior specificity of CBA and justifies caution in interpreting AQP4-IgG results obtained by ELISA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25178362     DOI: 10.1001/jamaneurol.2014.1581

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  16 in total

1.  Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning.

Authors:  Elias S Sotirchos; Angeliki Filippatou; Kathryn C Fitzgerald; Sara Salama; Santiago Pardo; Jiangxia Wang; Esther Ogbuokiri; Norah J Cowley; Nicole Pellegrini; Olwen C Murphy; Maureen A Mealy; Jerry L Prince; Michael Levy; Peter A Calabresi; Shiv Saidha
Journal:  Mult Scler       Date:  2019-07-31       Impact factor: 6.312

2.  Clinical and radiological characteristics of neuromyelitis optica spectrum disorder in the North Egyptian Nile Delta.

Authors:  Sara Salama; Hazem Marouf; M Ihab Reda; Amal R Mansour; Osama ELKholy; Michael Levy
Journal:  J Neuroimmunol       Date:  2018-08-29       Impact factor: 3.478

3.  Neuroimmunology: towards more-accurate diagnosis in neuromyelitis optica.

Authors:  Kazuo Fujihara; Jacqueline Palace
Journal:  Nat Rev Neurol       Date:  2014-11-11       Impact factor: 42.937

4.  Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum.

Authors:  Eoin P Flanagan; Philippe Cabre; Brian G Weinshenker; Jennifer St Sauver; Debra J Jacobson; Masoud Majed; Vanda A Lennon; Claudia F Lucchinetti; Andrew McKeon; Marcelo Matiello; Nilifur Kale; Dean M Wingerchuk; Jay Mandrekar; Jessica A Sagen; James P Fryer; Angala Borders Robinson; Sean J Pittock
Journal:  Ann Neurol       Date:  2016-04-04       Impact factor: 10.422

5.  Clinical pitfall: false-positive aquaporin-4 IgG leading to misdiagnosis of neuromyelitis optica spectrum disorder in patient with spinal arteriovenous fistula.

Authors:  Suradech Suthiphosuwan; Jiwon Oh; Aditya Bharatha
Journal:  Spinal Cord Ser Cases       Date:  2017-05-25

Review 6.  Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica.

Authors:  Jeffrey L Bennett
Journal:  J Neuroophthalmol       Date:  2016-09       Impact factor: 3.042

7.  Expanding the range of immunopathology in neuromyelitis optica spectrum disorder.

Authors:  Jennifer Massey; Michael E Buckland; Yael Barnett; Ian Sutton
Journal:  BMJ Case Rep       Date:  2016-07-28

8.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

Review 9.  Demographic and clinical features of neuromyelitis optica: A review.

Authors:  L Pandit; N Asgari; M Apiwattanakul; J Palace; F Paul; M I Leite; I Kleiter; T Chitnis
Journal:  Mult Scler       Date:  2015-04-28       Impact factor: 6.312

Review 10.  Update on biomarkers in neuromyelitis optica.

Authors:  Esther Melamed; Michael Levy; Patrick J Waters; Douglas Kazutoshi Sato; Jeffrey L Bennett; Gareth R John; Douglas C Hooper; Albert Saiz; Amit Bar-Or; Ho Jin Kim; Lakha Pandit; Maria Isabel Leite; Nasrin Asgari; Najib Kissani; Rogier Hintzen; Romain Marignier; Sven Jarius; John Marcelletti; Terry J Smith; Michael R Yeaman; May H Han; Orhan Aktas; Metha Apiwattanakul; Brenda Banwell; Denis Bichuetti; Simon Broadley; Philippe Cabre; Tanuja Chitnis; Jerome De Seze; Kazuo Fujihara; Benjamin Greenberg; Kerstin Hellwig; Raffaele Iorio; Sven Jarius; Eric Klawiter; Ingo Kleiter; Marco Lana-Peixoto; Kevin O'Connor; Jacqueline Palace; Friedman Paul; Naraporn Prayoonwiwat; Klemens Ruprecht; Olaf Stuve; Thomas Tedder; Silvia Tenembaum; Juan P Garrahan; Buenos Aires; Katja van Herle; Danielle van Pelt; Pablo Villoslada; Emmanuelle Waubant; Brian Weinshenker; Dean Wingerchuk; Jens Würfel; Scott Zamvil
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.